Monitoring and Measuring Drug Effects. I. Physical Effects

  • Alan J. Zametkin
  • Emily M. Yamada
Chapter

Abstract

The decision to use psychoactive medications in children and adolescents is not taken lightly by parents or clinicians. Medications are often utilized after periods of behavioral therapy or psychotherapeutic approaches have failed to ameliorate adequately the presenting symptoms.

Keywords

Tardive Dyskinesia Human Immune Deficiency Virus Neurological Exam Psychoactive Medication Positron Emission Tomog 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Abramowicz M: Sudden death in children treated with a tricyclic antidepressant. Med Lett Drugs Ther 32: 53, 1990.Google Scholar
  2. 2.
    Riddle MA, Nelson JC, Kleinman CS, et al: Sudden death in children receiving Norpramin: A review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry 30: 104–108, 1991.PubMedCrossRefGoogle Scholar
  3. 3.
    Gittelman-Klein R, Spitzer RL, Cantwell D: Diagnostic classifications and psychopharmacological indications, in Werry JS (ed): Pediatric Psychopharmacology: The Use of Behavior Modifying Drugs in Children. New York, Brunner/Mazel, 1978, pp 136–167.Google Scholar
  4. 4.
    Campbell M, Palij, M: Measurement of side effects including tardive dyskinesia, Psychopharmacology Bulletin: Rating Scales and Assessment Instruments for Use in Pediatric Psychopharmacology Research. National Institute of Mental Health, 21(4): 1063–1066, 1985.Google Scholar
  5. 5.
    Psychopharmacology Bulletin: Rating Scales and Assessment Instruments for Use in Pediatric Psychopharmacology Research. National Institute of Mental Health, 21 (4), 1985.Google Scholar
  6. 6.
    Guy W: Dosage Record and Treatment Emergent Symptoms Scale, ECDEU Assessment Manual for Psychopharmacology (Revised). US Department of Health, Education and Human Welfare publication (ADM) 76-338, 1976, pp 223–244.Google Scholar
  7. 7.
    Guy W: Treatment Emergent Symptoms Scale—Write-In, ECDEU Assessment Manual for Psychopharmacology (Revised). US Department of Health, Education and Human Welfare publication (ADM) 76-338, 1976, pp 341–345.Google Scholar
  8. 8.
    Guy W: Subjects Treatment Emergent Symptoms Scale, ECDEU Assessment Manual for Psychopharmacology (Revised). US Department of Health, Education and Human Welfare publication (ADM) 76-338, 1976, pp 347–350.Google Scholar
  9. 9.
    Guy W: Abnormal Involuntary Movement Scale, ECDEU Assessment Manual for Psychopharmacology (Revised). US Department of Health, Education and Human Welfare publication (ADM) 76-338, 1976, pp 534–537.Google Scholar
  10. 10.
    Campbell M, Green WH, Deutsch SI: Child and Adolescent Psychopharmacology. Beverly Hills, Sage Publications, 1985, pp 11–42.Google Scholar
  11. 11.
    Guy W: Physical and Neurological Examination for Soft Signs, ECDEU Assessment Manual for Psychopharmacology (Revised). US Department of Health, Education and Human Welfare publication (ADM) 76-338, 1976, pp 383–406.Google Scholar
  12. 12.
    Denckla MB: Revised neurological examination for subtle signs, Psychopharmacology Bulletin: Rating Scales and Assessment Instruments for Use in Pediatric Psychopharmacology Research. National Institute of Mental Health, 21(4): 773–789, 1985.Google Scholar
  13. 13.
    Sleator EK: Measurement of compliance, Psychopharmacology Bulletin: Rating Scales and Assessment Instruments for Use in Pediatric Psychopharmacology Research. National Institute of Mental Health, 21(4): 1089–1093, 1985.Google Scholar
  14. 14.
    Khan AU: Biochemical profile of depressed adolescents. J Am Acad Child Adolesc Psychiatry 6: 873–878, 1987.CrossRefGoogle Scholar
  15. 15.
    Doherty M, Madansky D, Kraft J, et al: Cortisol dynamics and test performance of the dexamethasone suppression test in 97 psychiatrically hospitalized children aged 3-16 years. J Am Acad Child Psychiatry 25(3): 400–408, 1986.CrossRefGoogle Scholar
  16. 16.
    Klee S, Garfinkel B: Identification of depression in children and adolescents: The role of the dexamethasone suppression test. J Am Acad Child Psychiatry 23: 410–415, 1984.PubMedCrossRefGoogle Scholar
  17. 17.
    Kinsbourne M: Disorders of mental development, in Menkes JH (ed): Textbook of Child Neurology, ed 3. Philadelphia, Lea & Febiger, 1985, pp 764–801.Google Scholar
  18. 18.
    Raj A, Sheehan D: Medical evaluation of panic attacks. J Clin Psychiatry 48: 309–313, 1987.PubMedGoogle Scholar
  19. 19.
    Zametkin A, Rapoport J: Neurobiology of attention deficit disorder with hyperactivity: Where have we come in 50 years? J. Am Acad Child Adolesc Psychiatry 26: 676–686, 1987.PubMedCrossRefGoogle Scholar
  20. 20.
    Bowden CL, Deutsch CK, Swanson JM: Plasma dopamine beta hydroxylase and platelet monoamine oxidase in attention deficit disorder and conduct disorder. J Am Acad Child Adolesc Psychiatry 27: 171–174, 1988.PubMedCrossRefGoogle Scholar
  21. 21.
    Kruesi MJP: Cruelty to animals and CSF 5-HIAA. Psychiatry Res 28: 115–116, 1989.PubMedCrossRefGoogle Scholar
  22. 22.
    Kruesi MJP, Linnoila M, Rapoport JL, et al: Carbohydrate craving, conduct disorder and low CSF 5-HIAA. Psychiatry Res 16: 83–86, 1985.PubMedCrossRefGoogle Scholar
  23. 23.
    Kruesi MJP, Rapoport JL, Hamburger S, et al: CSF monoamine metabolites, aggression and impulsivity in disruptive behavior disorders of children and adolescents. Arch Gen Psychiatry 47: 419–426, 1990.PubMedCrossRefGoogle Scholar
  24. 24.
    Diederich N, Ackerman R, Jurgens R, et al: Early involvement of the nervous system by human immune deficiency virus (HIV): A study of 79 patients. Eur Neurol 28: 93–103, 1988.PubMedCrossRefGoogle Scholar
  25. 25.
    Leckman JF, Weissman MM, Pauls DL: Family-genetic studies and identification of valid diagnostic categories in adult and child psychiatry, Br J Psychiatry 151: 39–44, 1987.PubMedCrossRefGoogle Scholar
  26. 26.
    Walzer S, et al: A method for the longitudinal study of behavioral development in infants and children: The early development of XXY children. J Child Psychol Psychiatry 19: 213–229, 1978.PubMedCrossRefGoogle Scholar
  27. 27.
    Ratcliffe SG, Field MAS: Emotional disorder of XYY children: Four case reports. J Child Psychol Psychiatry 23: 401–406, 1982.PubMedCrossRefGoogle Scholar
  28. 28.
    Nielsen J, Pelsen B, Sorenson K: Follow-up of 30 Klinefelter males treated with testosterone. Clin Genet 33: 262–269, 1988.PubMedCrossRefGoogle Scholar
  29. 29.
    Dening T, Berrios G: Wilson’s disease: Psychiatric symptoms in 195 cases. Arch Gen Psychiatry 46: 1126–1134, 1989.PubMedCrossRefGoogle Scholar
  30. 30.
    Courchesne E, Yeung-Courchesne R, Press G, et al: Hypoplasia of cerebellar vermal lobules VI and VII in autism. N Engl J Med 318: 1349–1354, 1988.PubMedCrossRefGoogle Scholar
  31. 31.
    Chugani H: Personal communication.Google Scholar
  32. 32.
    Gwirtsman HE, Kaye WH, George DT, et al: Hyperamylasemia and its relationship to binge-purge episodes: Development of a clinically relevant laboratory test. J Clin Psychiatry 50(6): 196–204, 1989.PubMedGoogle Scholar
  33. 33.
    Schoonover SC: Introduction: The practice of pharmacotherapy, in Bassuk EL, Schoonover SC, Gelenberg AJ (ed): The Practitioner’s Guide to Psychoactive Drugs, ed 2. New York, Plenum Press, 1983, pp 10–11.Google Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Alan J. Zametkin
    • 1
  • Emily M. Yamada
    • 1
  1. 1.Section on Clinical Brain Imaging, Laboratory of Cerebral MetabolismNational Institute of Mental HealthBethesdaUSA

Personalised recommendations